Search
Children globally have been profoundly impacted by the coronavirus disease 2019 (COVID-19) pandemic. This review explores the direct and indirect public health impacts of COVID-19 on children. We discuss in detail the transmission dynamics, vaccination strategies and, importantly, the ‘shadow pandemic’, encompassing underappreciated indirect impacts of the pandemic on children.
Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
The meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) is licensed for use in children aged 10 years or older for protection against invasive serogroup B meningococcal disease. Because young children are at increased risk of invasive meningococcal disease, MenB-FHbp clinical data in this population are needed.
Streptococcus pneumoniae (the pneumococcus) is a human pathogen of global importance, classified into serotypes based on the type of capsular polysaccharide produced. Serotyping of pneumococci is essential for disease surveillance and vaccine impact measurement.
Clinical Research Manager
Head, Infectious Disease Implementation Research
Researchers at The Kids Research Institute Australia have helped map the global impact of life saving vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation (EPI).
Dr Lea-Ann Kirkham and Dr Chris Blyth have been appointed as Co-Directors
A new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.
Toddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.